- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01064947
Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis
Use of Altabax Ointment (Retapamulin 1%) BID for 7 Days in Treatment of Secondary Infection With Staphylococcus Aureus (MRSA and MSSA) and Streptococcus Pyogenes in Atopic Dermatitis Patients - Open Label Pilot Study
Skin infections may complicate the treatment of atopic dermatitis.The use of topical ointments has become very important to avoid the use of oral antibiotics. There is little supporting literature regarding the use of topical antibiotics in secondarily infected atopic dermatitis.
This study will investigate the safety and effectiveness of Altabax ointment use in treating secondarily infected atopic dermatitis caused by Staphylococcus aureus and Streptococcus pyogenes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Atopic dermatitis patients are commonly secondarily infected with Staphylococcus aureus and/or Streptococcus pyogenes, more recently with Methicillin-resistant Staphylococcus aureus (MRSA), due to impaired barrier function. As cutaneous infections such as MRSA and others may complicate the treatment of atopic dermatitis, the use of topical antibiotics have become very important to avoid oral antibiotics and their side effects, especially in the pediatric population.
The current study will investigate the safety and efficacy of Altabax ointment use for treatment of secondarily infected lesions caused by Staphylococcus aureus and Streptococcus pyogenes in both the pediatric and adult populations.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Kentucky
-
Louisville, Kentucky, United States, 40217
- DermResearch, PLLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female subjects of childbearing potential must have a negative urine pregnancy test at Baseline and practice a reliable method of contraception.
- Secondary infection of atopic dermatitis with S.aureus or S.pyogenes as the probable causative agent.
- An infected area less than or equal to 100 centimeters squared for subjects 18 years of age or older, or, 2% body surface area for subjects under 18 years of age.
- Skin Infection Rating Scale score greater than or equal to 8.
- Able to understand and comply with the requirements of the study and sign Informed Consent/Health Insurance Portability and Accountability Authorization Forms. Subjects under the legal age of consent must also have the written informed consent of parent or legal guardian.
Exclusion Criteria:
- Female subjects who are pregnant, trying to get pregnant, breast feeding or who are of childbearing potential and not practicing reliable birth control.
- Allergic to any component of the test medication.
- Clinical diagnosis of impetigo, folliculitis or minor soft tissue infection.
- Use of topical antibacterial medication to the study treatment area within 1 day of Visit 1.
- Signs of systemic infection or evidence of abcess or cellulitis at the site to be treated.
- Medical condition that,in the opinion of the investigator, contraindicates the subject's participation in the clinical study.
- Recent alcohol or drug abuse is evident.
- History of poor cooperation, non-compliance with medical treatment or unreliability.
- Participation in an investigational drug study within 30 days of Baseline Visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bacteriological Culture
Time Frame: Day 1 and Day 7
|
All participants were cultured for S.aureus (MRSA), S.aureus (MSSA) and S. pyogenes at Baseline.
If positive at Baseline then they were cultured again at Day 7.
|
Day 1 and Day 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skin Infection Rating Scale (SIRS)
Time Frame: Day 1 and Day 7
|
The Primary Investigator rated the each of the following characteristics: exudate/pus, crusting, erythema/inflammation, tissue warmth, tissue edema, itching and pain on a scale of 0-6 (absent-severe) to create an overall SIRS score ranging from 0-42.
|
Day 1 and Day 7
|
Investigator Assessment of Clinical Cure
Time Frame: Day 7
|
The investigator assessed clinical cure at Day 7 as either total or improved cure, failure confirmed or failure by default
|
Day 7
|
Local Tolerability
Time Frame: Day 7
|
The investigator assessed the following characteristics on a grading scale of 0-3 (none, mild moderate or severe): erythema, inflammation, infection, crusting, necrosis, peeling, swelling and contact dermatitis. The subject assessed the following characteristics on a scale of 0-3 (none, mild, moderate or severe): irritation, itchiness burning, tenderness and pain. |
Day 7
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Leon H. Kircik, M.D., DermResearch, PLLC
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Immune System Diseases
- Neoplasms
- Hypersensitivity, Immediate
- Genetic Diseases, Inborn
- Skin Diseases, Genetic
- Neoplastic Processes
- Hypersensitivity
- Skin Diseases, Eczematous
- Infections
- Neoplasm Metastasis
- Dermatitis
- Eczema
- Dermatitis, Atopic
- Coinfection
- Anti-Infective Agents
- Anti-Bacterial Agents
- Retapamulin
Other Study ID Numbers
- ALT113706
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on Retapamulin 1%
-
Ferrer Internacional S.A.CompletedEfficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With ImpetigoImpetigoGermany, South Africa
-
GlaxoSmithKlineCompletedSkin Infections, BacterialUnited States, Germany, Taiwan, Netherlands, Argentina, Chile, Costa Rica, South Africa, Mexico
-
GlaxoSmithKlineCompletedSkin Infections, BacterialUnited States, South Africa, India, Argentina, Brazil
-
GlaxoSmithKlineCompletedSkin Infections, BacterialNetherlands, Costa Rica, Germany, Mexico, Canada, India, Poland, South Africa, France, Peru
-
Gary GoldenbergCompletedHand Eczema | Foot EczemaUnited States
-
GlaxoSmithKlineCompletedImpetigoIndia, Mexico, Netherlands, Italy, Peru
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
The University of Texas Health Science Center,...GlaxoSmithKlineCompletedFolliculitis | Impetigo | Secondarily Infected Eczema | Minor Soft Tissue InfectionsUnited States
-
GlaxoSmithKlineCompletedSkin Infections, BacterialKorea, Republic of
-
GlaxoSmithKlineCompleted